# AMPD1

## Overview
The AMPD1 gene encodes the enzyme adenosine monophosphate deaminase 1, which plays a critical role in the purine nucleotide cycle, particularly within skeletal muscle tissue. This enzyme is categorized as a deaminase and is essential for the conversion of adenosine monophosphate (AMP) to inosine monophosphate (IMP), a process vital for maintaining energy homeostasis during muscle contraction. The AMPD1 protein is predominantly expressed in fast-twitch glycolytic fibers, reflecting its importance in energy metabolism during high-intensity exercise. Genetic mutations in AMPD1 can lead to myoadenylate deaminase deficiency, a condition marked by exercise intolerance and muscle fatigue. Despite its association with muscle dysfunction, certain mutations in AMPD1 have been linked to protective effects in cardiovascular conditions, illustrating the gene's multifaceted role in human health (Zabielska2015Inhibition; Sabina1984Myoadenylate; Norman2001Regulation; Morisaki1993Functionally).

## Structure
The AMPD1 gene encodes the adenosine monophosphate deaminase 1 enzyme, which is predominantly expressed in skeletal muscle. The primary structure of the AMPD1 protein consists of 747 amino acids, encoded by a sequence of 22,455 base pairs and 16 exons (Safranow2010AMPD1). The protein features a conserved C-terminal domain of approximately 550 amino acids, which includes a catalytic center motif SLSTDDP, crucial for its enzymatic activity (He2010A).

The secondary structure of AMPD1 includes alpha helices and beta sheets, contributing to its complex allosteric nature (He2010A). The tertiary structure involves the three-dimensional folding necessary for its function in the purine nucleotide cycle, although specific details on the tertiary structure are not provided in the context.

AMPD1 may undergo post-translational modifications, such as methylation, which can influence its function and involvement in disease (Mohamed2023In). The gene also produces splice variant isoforms through alternative splicing, which can result in transcripts with or without miniexon 2, though this splicing does not affect the enzyme's catalytic activity (MahnkeZizelman1992Cloning). These structural features are essential for the enzyme's role in energy metabolism and muscle function.

## Function
The AMPD1 gene encodes the enzyme adenosine monophosphate deaminase 1, which is crucial for energy metabolism in skeletal muscle cells. This enzyme catalyzes the deamination of adenosine monophosphate (AMP) to inosine monophosphate (IMP), a key step in the purine nucleotide cycle. This process is particularly important during short-term, high-intensity exercise when the rate of ATP utilization exceeds the cell's capacity to resynthesize ATP. By converting AMP to IMP, AMPD1 helps prevent the accumulation of adenosine diphosphate (ADP), thereby maintaining a favorable ATP-to-ADP ratio essential for muscle contraction (Norman2001Regulation; Morisaki1993Functionally).

AMPD1 is predominantly expressed in skeletal muscle, with its activity being significantly higher in fast-twitch glycolytic fibers compared to slow-twitch oxidative fibers. This expression pattern underscores its role in muscle-specific energy metabolism (Morisaki1993Functionally). The enzyme's activity is regulated by tissue-specific signals, and its expression is crucial for maintaining normal muscle function. Deficiency in AMPD1 activity, often due to genetic mutations, can lead to metabolic myopathy, characterized by exercise intolerance and muscle fatigue (Sabina1990Characterization; Morisaki1993Functionally).

## Clinical Significance
Mutations in the AMPD1 gene can lead to myoadenylate deaminase deficiency (MDD), a condition characterized by disruptions in the purine nucleotide cycle, particularly affecting skeletal muscle function. This deficiency often results in symptoms such as muscle fatigue, exercise intolerance, and post-exertional muscle cramps (Sabina1984Myoadenylate). The C34T mutation in the AMPD1 gene is a common cause of MDD, leading to a truncated, inactive enzyme and the accumulation of AMP in muscle tissue (Rannou2017Effects). This mutation is prevalent in the Caucasian population, with 2-3% being homozygous, and is associated with skeletal myopathy (Zabielska2015Inhibition).

Despite its association with muscle dysfunction, the C34T mutation has been found to confer benefits in certain cardiovascular conditions, such as heart failure, by reducing tissue injury during ischemia and improving vasodilatory responses due to increased adenosine production (Zabielska2015Inhibition). Other mutations, such as R388W and R425H, have been identified in Japanese patients, leading to myopathy that cannot be compensated by alternative splicing, suggesting ethnic variability in clinical presentation (Morisaki2000First). These findings highlight the complex role of AMPD1 mutations in both muscle and cardiovascular health.

## Interactions
The AMPD1 protein is involved in several interactions with other proteins, particularly within the purine nucleotide cycle. It interacts with a network of proteins that are crucial for various metabolic processes. Notably, AMPD1 interacts with proteins such as ADK, ADSS, ADSSL1, ADSL, APRT, ATIC, ITPA, HPRT1, GMPR, and IMPDH2. These interactions are significant in metabolic and biosynthetic processes involving nucleobase-containing small molecules, nucleoside phosphate, purine nucleotide, and carbohydrate derivatives (Mohamed2023In).

The AMPD1 protein also plays a role in maintaining a high ATP:ADP ratio during muscle contraction and is involved in the purine cycle, which generates ammonium to counteract acidic pH from fermentation. It interacts with contractile proteins such as myosin to maintain their activity and regulation (Camici2018Interplay).

Additionally, AMPD1 is implicated in the regulation of the mTORC1-p70 S6 kinase axis, influencing insulin sensitivity in skeletal muscle. AMPD1 deficiency enhances the activation of AMPK, Akt, and p70 S6 kinase, suggesting a regulatory role in the mTOR signaling pathway, particularly under high-fat diet conditions (Tandelilin2015AMPD1).


## References


[1. (Morisaki2000First) Hiroko Morisaki, Itsuro Higuchi, Mayumi Abe, Mitsuhiro Osame, and Takayuki Morisaki. First missense mutations (r388w and r425h) of ampd1 accompanied with myopathy found in a japanese patient. Human Mutation, 16(6):467–472, 2000. URL: http://dx.doi.org/10.1002/1098-1004(200012)16:6<467::AID-HUMU3>3.0.CO;2-V, doi:10.1002/1098-1004(200012)16:6<467::aid-humu3>3.0.co;2-v. This article has 18 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/1098-1004(200012)16:6)

[2. (Sabina1984Myoadenylate) R L Sabina, J L Swain, C W Olanow, W G Bradley, W N Fishbein, S DiMauro, and E W Holmes. Myoadenylate deaminase deficiency. functional and metabolic abnormalities associated with disruption of the purine nucleotide cycle. Journal of Clinical Investigation, 73(3):720–730, March 1984. URL: http://dx.doi.org/10.1172/jci111265, doi:10.1172/jci111265. This article has 100 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci111265)

[3. (Rannou2017Effects) Fabrice Rannou, Virginie Scotet, Pascale Marcorelles, Roxane Monnoyer, and Cédric Le Maréchal. Effects of ampd1 common mutation on the metabolic-chronotropic relationship: insights from patients with myoadenylate deaminase deficiency. PLOS ONE, 12(11):e0187266, November 2017. URL: http://dx.doi.org/10.1371/journal.pone.0187266, doi:10.1371/journal.pone.0187266. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0187266)

[4. (Safranow2010AMPD1) Krzysztof Safranow, Janina Suchy, Katarzyna Jakubowska, Maria Olszewska, Agnieszka Bińczak-Kuleta, Grzegorz Kurzawski, Ryszard Rzeuski, Edyta Czyżycka, Beata Łoniewska, Zdzisława Kornacewicz-Jach, Andrzej Ciechanowicz, and Dariusz Chlubek. Ampd1 gene mutations are associated with obesity and diabetes in polish patients with cardiovascular diseases. Journal of Applied Genetics, 52(1):67–76, November 2010. URL: http://dx.doi.org/10.1007/s13353-010-0009-x, doi:10.1007/s13353-010-0009-x. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s13353-010-0009-x)

[5. (Norman2001Regulation) Barbara Norman, Richard L. Sabina, and Eva Jansson. Regulation of skeletal muscle atp catabolism by ampd1 genotype during sprint exercise in asymptomatic subjects. Journal of Applied Physiology, 91(1):258–264, July 2001. URL: http://dx.doi.org/10.1152/jappl.2001.91.1.258, doi:10.1152/jappl.2001.91.1.258. This article has 53 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1152/jappl.2001.91.1.258)

[6. (He2010A) Hua He, Xiaolin Liu, Yulan Gu, and Yu Liu. A novel 18-bp deletion mutation of the ampd1 gene affects carcass traits in qinchuan cattle. Molecular Biology Reports, 37(8):3945–3949, March 2010. URL: http://dx.doi.org/10.1007/s11033-010-0052-z, doi:10.1007/s11033-010-0052-z. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s11033-010-0052-z)

[7. (Tandelilin2015AMPD1) Andreas AK Tandelilin, Tetsuaki Hirase, Athanasius W Hudoyo, Jidong Cheng, Keiko Toyama, Hiroko Morisaki, and Takayuki Morisaki. Ampd1 regulates mtorc1-p70 s6 kinase axis in the control of insulin sensitivity in skeletal muscle. BMC Endocrine Disorders, March 2015. URL: http://dx.doi.org/10.1186/s12902-015-0010-9, doi:10.1186/s12902-015-0010-9. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12902-015-0010-9)

[8. (Sabina1990Characterization) R L Sabina, T Morisaki, P Clarke, R Eddy, T B Shows, C C Morton, and E W Holmes. Characterization of the human and rat myoadenylate deaminase genes. Journal of Biological Chemistry, 265(16):9423–9433, June 1990. URL: http://dx.doi.org/10.1016/s0021-9258(19)38866-0, doi:10.1016/s0021-9258(19)38866-0. This article has 87 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/s0021-9258(19)38866-0)

[9. (Zabielska2015Inhibition) Magdalena A. Zabielska, Tomasz Borkowski, Ewa M. Slominska, and Ryszard T. Smolenski. Inhibition of amp deaminase as therapeutic target in cardiovascular pathology. Pharmacological Reports, 67(4):682–688, August 2015. URL: http://dx.doi.org/10.1016/j.pharep.2015.04.007, doi:10.1016/j.pharep.2015.04.007. This article has 30 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.pharep.2015.04.007)

[10. (MahnkeZizelman1992Cloning) D.K. Mahnke-Zizelman and R.L. Sabina. Cloning of human amp deaminase isoform e cdnas. evidence for a third ampd gene exhibiting alternatively spliced 5’-exons. Journal of Biological Chemistry, 267(29):20866–20877, October 1992. URL: http://dx.doi.org/10.1016/s0021-9258(19)36768-7, doi:10.1016/s0021-9258(19)36768-7. This article has 61 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/s0021-9258(19)36768-7)

[11. (Morisaki1993Functionally) Takayuki Morisaki and Edward W. Holmes. Functionally distinct elements are required for expression of the ampd1 gene in myocytes. Molecular and Cellular Biology, 13(9):5854–5860, September 1993. URL: http://dx.doi.org/10.1128/mcb.13.9.5854-5860.1993, doi:10.1128/mcb.13.9.5854-5860.1993. This article has 0 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.13.9.5854-5860.1993)

[12. (Camici2018Interplay) Marcella Camici, Simone Allegrini, and Maria Grazia Tozzi. Interplay between adenylate metabolizing enzymes and amp‐activated protein kinase. The FEBS Journal, 285(18):3337–3352, May 2018. URL: http://dx.doi.org/10.1111/febs.14508, doi:10.1111/febs.14508. This article has 33 citations.](https://doi.org/10.1111/febs.14508)

[13. (Mohamed2023In) Abrar Mohamed, Abdelrahman Hamza, Hiba Fadl, Afra Albkrye, Hadeel Ahmed, Hazem Abubaker, and Sahar Elbager. In silico approach for identification, prediction of ampd1 gene nssnps associated with myoadenylate deaminase deficiency. Journal of Bioscience and Applied Research, 0(0):0–0, February 2023. URL: http://dx.doi.org/10.21608/jbaar.2023.284727, doi:10.21608/jbaar.2023.284727. This article has 1 citations.](https://doi.org/10.21608/jbaar.2023.284727)